Outcomes and Toxicities of Definitive Radiation Therapy for Unresected Thymic Malignancies
JTO Clinical and Research Reports · 2026-05 · 7 (5) · 100970
DOI: 10.1016/j.jtocrr.2026.100970 ↗Kurz gefasst
Fachartikel in der Zeitschrift JTO Clinical and Research Reports, 2026-05. Verfasst von Sana Raoof und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Introduction
Thymic malignancies are primarily managed with surgery. Some patients are medically inoperable or technically unresectable. We report the characteristics and outcomes of patients with unresected thymic tumors treated with definitive radiation therapy (RT) at our institution.
Methods
Patients treated with curative-intent RT for unresected thymic tumors between 1997 and 2023 were identified. Age at diagnosis, sex, histology, Masaoka or TNM stage, WHO classification, reason for no resection, RT dose and fractionation, presence of paraneoplastic syndrome, chemotherapy use, and toxicities were extracted. Overall and local failure-free survival, patterns of progression, and treatment toxicities were assessed. This retrospective chart review did not require informed consent.
Results
A total of 33 consecutive patients were identified (16 females and 17 males) with a median age of 61 years at diagnosis. Overall, 22 patients had thymoma and 11 had thymic carcinoma. T stage was T2 (one), T3 (seven), and T4 (25); N stage was N0 (15), N1 (one), and N2 (17); M stage was M0 (21), M1a (eight), and M1b (four). Median tumor size was 8.1 cm. Three patients were medically inoperable; 30 were technically unresectable. Of the 33 patients, 29 received chemotherapy. The median RT dose was 60 Gy in 2 Gy fractions.Furthermore, 6% developed a grade 3 toxicity and 9% developed grade 2 pneumonitis. No grade 4/5 toxicities were observed. The 2-year overall survival was 69% (95% confidence interval [CI]: 52-92) and 5-year overall survival was 56% (95% CI: 37-85). The 3- and 5-year local failure rates were 20% (95% CI: 6.9-39).
Conclusions
In the most advanced stage and one of the largest reports to date, definitive chemo-RT provides high rates of local control in patients with unresected thymic malignancies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
- Division of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington.
- New York Proton Center, New York, New York.
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Förderung
- NCI NIH HHS
Zitieren
APA
Raoof, S., Toumbacaris, N., Shepherd, A. F., Gelblum, D. Y., Simone, C. B., Wu, A. J., Yorke, E. D., Ginsberg, M. S., Pagano, A. M., Huang, J., Riely, G. J., Zhang, Z., & Rimner, A. (2026). Outcomes and Toxicities of Definitive Radiation Therapy for Unresected Thymic Malignancies. JTO Clinical and Research Reports, 7(5), 100970. https://doi.org/10.1016/j.jtocrr.2026.100970
Vancouver
Raoof S, Toumbacaris N, Shepherd AF, Gelblum DY, Simone CB, Wu AJ, et al. Outcomes and Toxicities of Definitive Radiation Therapy for Unresected Thymic Malignancies. JTO Clinical and Research Reports. 2026;7(5):100970. doi:10.1016/j.jtocrr.2026.100970
BibTeX
@article{Raoof2026,
author = {Raoof, Sana and Toumbacaris, Nicolas and Shepherd, Annemarie F and Gelblum, Daphna Y and Simone, Charles B and Wu, Abraham J and Yorke, Ellen D and Ginsberg, Michelle S and Pagano, Andrew M and Huang, James and Riely, Gregory J and Zhang, Zhigang and Rimner, Andreas},
title = {Outcomes and Toxicities of Definitive Radiation Therapy for Unresected Thymic Malignancies},
journal = {JTO Clinical and Research Reports},
year = {2026},
volume = {7},
number = {5},
pages = {100970},
doi = {10.1016/j.jtocrr.2026.100970}
}
EUVIMED